Use of vonoprazan,a novel potassium-competitive acid blocker,for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis

Abstract

Objective:

Proton pump inhibitor-refractory reflux esophagitis is one of the intractable conditions of systemic sclerosis for which new treatments are required. Vonoprazan is a novel potassium-competitive acid blocker and has been shown to have several advantages over conventional proton pump inhibitors, including a long duration of gastric acid suppression.

Methods:

To investigate the efficacy of vonoprazan for treating proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis, 10 patients with proton pump inhibitor-refractory reflux esophagitis who were switched to vonoprazan were selected from our systemic sclerosis database. Reflux esophagitis was evaluated by endoscopy, and gastroesophageal reflux disease–related symptoms were assessed by the frequency scale for the symptoms of gastroesophageal reflux disease questionnaire before and after switching from proton pump inhibitor to vonoprazan at an average interval of 3.5 [2–5.5] months.

Results:

After switching patients to vonoprazan, the endoscopic findings of reflux esophagitis were significantly improved (p = .033), and six patients (60%) achieved mucosal healing. The total frequency scale for the symptoms of gastroesophageal reflux disease score was also significantly decreased (p = .043), mainly by improving the acid reflux score. Vonoprazan was well tolerated and was continued for 15.5 [11.25–23.75] months in all patients.

Conclusion:

Vonoprazan is a potential treatment option for treating proton pump inhibitor-refractory reflux esophagitis in systemic sclerosis patients.

Keywords

Gastroesophageal reflux disease gastrointestinal involvement proton pump inhibitor reflux esophagitis systemic sclerosis

Get full access to this article

View all access options for this article.

References

Varga

Trojanowska

Kuwana

Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017; 2(3): 137–152.

Shreiner

Murray

Denton

, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 2016; 1(3): 247–256.

Hoffmann-Vold

Volkmann

ER.

Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches. J Scleroderma Relat Disord 2021; 6(1): 37–43.

Kowal-Bielecka

Fransen

Avouac

, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76(8): 1327–1339.

Nagaraja

McMahan

Getzug

, et al. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol 2015; 1(1): 82–105.

Stern

Carlson

Falmagne

, et al. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil 2018; 30(2): 13247.

Sugano

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 2018; 11: 1756283X17745776.

Hoshino

Kawami

Takenouchi

, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017; 95(2): 156–161.

Yamashita

Kanamori

Kano

, et al. The effects of switching to vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion 2017; 96(1): 52–59.

10.

Akiyama

Hosaka

Kuribayashi

, et al. Efficacy of vonoprazan, a novel potassium-competitive acid locker, in patients with proton pump inhibitor-refractory acid reflux. Digestion 2020; 101(2): 174–183.

11.

van den Hoogen

Khanna

Fransen

, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2013; 65(11): 2737–2747.

12.

Shirai

Okazaki

Inoue

, et al. Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol 2015; 67(2): 498–507.

13.

Lundell

Dent

Bennett

, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45(2): 172–180.

14.

Kusano

Shimoyama

Sugimoto

, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004; 39(9): 888–891.

15.

Kuribayashi

Iwakiri

Shinozaki

, et al. Clinical impact of different cut-off values in high-resolution manometry systems on diagnosing esophageal motility disorders. J Gastroenterol 2019; 54(12): 1078–1082.

16.

Kahrilas

Bredenoord

Fox

, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27(2): 160–174.

17.

Sakurai

Mori

Okamoto

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42(6): 719–730.